Acadia Pharma (ACAD): No NUPLAZID Data Until Mid 2017 - HC Wainwright

September 23, 2016 8:38 AM EDT
Get Alerts ACAD Hot Sheet
Price: $27.24 +0.59%

Rating Summary:
    9 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade ACAD Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

H.C. Wainwright analyst, Andrew Fein, reiterated his Buy on Acadia Pharmaceuticals (NASDAQ: ACAD) after meeting with management but noted that he expects management to wait to provide metrics on how the launch is progressing toward the middle of 2017. This should lead to a tightening of consensus for 2H17.

No change to the price target of $60.00

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $34.98 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Management Comments

Related Entities

H.C. Wainwright

Add Your Comment